RxDoctor Payments Data

David Olson, MD

Internal Medicine · Oakdale, CANPI 1346252525

Payments from drug & device makers

$343in general payments, 2019–2025

Across 16 payments — averaging $21.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$137
  • Viiv Healthcare Company$72
  • Merck$62
  • Gilead$36
  • Shionogi Inc$22
  • Abbott$15

What the payments were for

  • Food & beverage$20660%
  • Education$13740%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$343 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$211,231
Medicare patients
370
Services billed
2,178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala86$418,529
CabenuvaCabotegravir/Rilpivirine31$209,992
TivicayDolutegravir Sodium88$194,733
DescovyEmtricitabine/Tenofov Alafenam45$102,708
TriumeqAbacavir/Dolutegravir/Lamivudi14$59,046
EliquisApixaban73$53,730
GenvoyaElviteg/Cob/Emtri/Tenof Alafen11$50,975
CompleraEmtricita/Rilpivirine/Tenof Df12$40,122
JardianceEmpagliflozin21$25,949
IsentressRaltegravir Potassium13$25,860
Efavirenz49$15,267
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)70$13,427
Lantus SolostarInsulin Glargine,hum.Rec.Anlog58$7,961
Spiriva RespimatTiotropium Bromide15$7,644
Diclofenac Sodium17$6,515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$36$572,213142 claims
Viiv Healthcare CompanyCabenuva, Tivicay, Triumeq$72$463,771133 claims
MerckIsentress, Janumet$62$31,91825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Oakdale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →